BTAI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioXcel Therapeutics Inc (BTAI) is not a strong buy for a beginner investor seeking long-term growth. The company has shown significant financial underperformance, with declining revenue and EPS, despite recent positive trial results. The technical indicators are neutral, and there are no strong proprietary trading signals or significant insider or hedge fund activity to suggest a compelling entry point. Given the investor's impatience and preference for long-term stability, holding off on this stock is recommended.
The MACD histogram is positive but contracting, RSI is neutral at 45.329, and moving averages are converging, suggesting no clear trend. The stock is trading below its pivot level of 1.667, with key support at 1.553 and resistance at 1.782.
Positive Phase 2 trial results for BXCL501, showing effectiveness in reducing opioid withdrawal symptoms and favorable tolerability. This led to a 20% pre-market surge on March 5, 2026.
Significant financial underperformance in Q3 2025, with revenue down 54.21% YoY and EPS dropping by 57.67%. Post-market decline of 5.41% following regular market loss of 2.42%.
In Q3 2025, revenue dropped 54.21% YoY to $98,000, EPS fell 57.67% YoY to -2.18, and gross margin declined 119.87% YoY to 88.78%. Net income improved to -$30.91M, up 126.45% YoY.
No recent analyst ratings or price target updates available.
